Navigation Links
Six-Month Prospective Multi-Center Study Reports Efficacy Rates for AMS' Elevate Anterior and Apical Prolapse Repair System
Date:3/10/2011

MINNEAPOLIS, March 10, 2011 /PRNewswire/ -- American Medical Systems® (AMS) (Nasdaq: AMMD), a leading provider of world-class devices and therapies for male and female pelvic health, today announced the results of a six-month prospective multi-center study of the Elevate® Anterior and Apical Prolapse Repair System. The pelvic organ prolapse quantification exam (POP-Q), used to quantify, describe and stage pelvic support, was implemented in the study and concluded efficacy rates of Stage One or less to be 86.3% for Anterior and 98.8% for Apical.  

The study was conducted with 142 women who were enrolled at 16 centers located in the United States and Europe. When questioned about quality of life benefits after receiving the procedure, 94.7 percent of patients reported feeling some or a lot of improvement.

"The Elevate Anterior and Apical system, completed with a single vaginal incision and no external needle passes, has shown at six months to be effective at treating both anterior and apical prolapse," said Dr. Edward J. Stanford, principal investigator of the study. "The results of this study were especially significant given that many of the patients had severe Stage Three or Four prolapse."

Elevate is a minimally invasive, comprehensive solution to treat anterior and apical defects. The total transvaginal approach is designed to minimize tissue trauma. Elevate offers safe, simple and precise apical mesh placement in the sacrospinous ligament through a single vaginal incision.

"We are very pleased to see these positive efficacy rates coupled with significant patient satisfaction," stated John Nealon, senior vice president and general manager of Women's Health at AMS. "This data continues to validate our technology and helps confirm why Elevate is the top-selling prolapse repair system in the market place."

The Elevate Anterior and Apical Prolapse Repair System is part of American Medical Systems' comprehensive portfolio of products designed to treat female incontinence and pelvic floor prolapse. For more information about AMS' complete line of female pelvic health solutions, visit www.americanmedicalsystems.com.

About American Medical Systems:

American Medical Systems, headquartered in Minnetonka, Minnesota, is a diversified supplier of medical devices and procedures to treat incontinence, erectile dysfunction, benign prostatic hyperplasia (BPH), pelvic floor prolapse and other pelvic disorders in men and women. These disorders can significantly diminish one's quality of life and profoundly affect social relationships. In recent years, the number of people seeking treatment has increased markedly as a result of longer lives, higher-quality-of-life expectations and greater awareness of new treatment alternatives. American Medical Systems' products reduce or eliminate the incapacitating effects of these diseases, often through minimally invasive therapies. The Company's products were used to treat approximately 340,000 patients in 2010.

More information about the Company and its products can be found at its website www.AmericanMedicalSystems.com and in the Company's Annual Report on Form 10-K for 2009 and its other SEC filings.


'/>"/>
SOURCE American Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
2. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
3. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
4. Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer
5. Zacks Rates CardioGenics Outperform With Six-Month Target of $1.22
6. NASDAQ Gives Dynatronics a Second Six-Month Extension for Minimum Bid Price Compliance
7. Prospective Microbial Analysis of Bronchoalveolar Lavage Fluids with Immune Function Testing Can Distinguish Between Fungal Colonization and Fungal Disease In Lung Transplant Recipients
8. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
9. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
10. Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study
11. Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , ... Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: A ... Results of the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, ... recognized for adherence to the highest standards of trauma, maternity, cancer and chronic ... center's president and CEO, Dr. Daniel Messina. , Among the recognitions, the American ...
(Date:12/8/2016)... ... ... Vida Health, the digital health platform that pairs individuals with ... . Other investors include Nokia Growth Partners (NGP) and returning investor Aspect Ventures. Vida ... are managing chronic conditions or simply want to improve their health. Canvas ...
(Date:12/8/2016)... ... ... Coppin Insurance Agency, an insurance and financial planning firm based in Lee ... is embarking on a charity drive with the goal of providing support and donations ... Bank of Southwest Florida works to provide fresh and nutritious food free of charge ...
Breaking Medicine News(10 mins):